Compare Bandhan Healthcare Fund vs ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund
Risk | Very High | Very High |
Rating | - | 5.0 |
Min SIP Amount | ₹100 | ₹100 |
Expense Ratio | 2.38 | 1.86 |
NAV | ₹9.72 | ₹37.51 |
Fund Started | 10 Nov 2025 | 25 Jun 2018 |
Fund Size | ₹291.59 Cr | ₹6455.55 Cr |
Exit Load | Exit load of 0.50%, if redeemed within 30 days. | Exit load of 1% if redeemed within 15 days. |
Risk
Very High
Very High
Rating
-
5.0
Min SIP Amount
₹100
₹100
Expense Ratio
2.38
1.86
NAV
₹9.72
₹37.51
Fund Started
10 Nov 2025
25 Jun 2018
Fund Size
₹291.59 Cr
₹6455.55 Cr
Exit Load
Exit load of 0.50%, if redeemed within 30 days.
Exit load of 1% if redeemed within 15 days.
1 Year | - | -1.54% |
3 Year | - | 25.69% |
5 Year | - | 16.06% |
1 Year
-
-1.54%
3 Year
-
25.69%
5 Year
-
16.06%
Equity | 73.81% | 97.87% |
Cash | 25.95% | 2.13% |
Equity
73.81%
97.87%
Cash
25.95%
2.13%
Top 10 Holdings |
|
|
Top 10 Holdings
Sun Pharmaceutical Industries Ltd. | 10.05% |
Apollo Hospitals Enterprise Ltd. | 7.55% |
Dr. Reddy's Laboratories Ltd. | 6.48% |
Cipla Ltd. | 6.30% |
Max Healthcare Institute Ltd. | 6.18% |
Divi's Laboratories Ltd. | 5.55% |
JB Chemicals & Pharmaceuticals Ltd. | 4.25% |
Ajanta Pharma Ltd. | 2.85% |
Syngene International Ltd. | 2.78% |
Glenmark Pharmaceuticals Ltd. | 2.00% |
Sun Pharmaceutical Industries Ltd. | 12.05% |
Cipla Ltd. | 7.90% |
Dr. Reddy's Laboratories Ltd. | 7.82% |
Divi's Laboratories Ltd. | 7.10% |
Mankind Pharma Ltd. | 6.44% |
Lupin Ltd. | 5.78% |
Aurobindo Pharma Ltd. | 5.19% |
Alkem Laboratories Ltd. | 3.66% |
Cohance Lifesciences Ltd. | 3.01% |
Syngene International Ltd. | 2.98% |
Name | Viraj Kulkarni | - |
Start Date | 10 Nov 2025 | - |
Name
Viraj Kulkarni
-
Start Date
10 Nov 2025
-
Description | The scheme seeks to generate long-term capital appreciation by investing predominantly in equity and equity-related instruments of companies engaged in Healthcare, Pharma and Allied sectors. | The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies. |
Launch Date | 10 Nov 2025 | 25 Jun 2018 |
Description
The scheme seeks to generate long-term capital appreciation by investing predominantly in equity and equity-related instruments of companies engaged in Healthcare, Pharma and Allied sectors.
The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies.
Launch Date
10 Nov 2025
25 Jun 2018